Clinical Trials Logo

Hepatitis B, Chronic clinical trials

View clinical trials related to Hepatitis B, Chronic.

Filter by:

NCT ID: NCT02981602 Completed - Hepatitis B Clinical Trials

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Start date: February 24, 2017
Phase: Phase 2
Study type: Interventional

To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection

NCT ID: NCT02979613 Completed - Chronic Hepatitis B Clinical Trials

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Start date: December 29, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT02967939 Completed - Clinical trials for Hepatitis B, Chronic

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Start date: March 28, 2017
Phase: Phase 3
Study type: Interventional

A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients

NCT ID: NCT02964910 Completed - Hepatitis E Clinical Trials

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )

Start date: August 2016
Phase: Phase 4
Study type: Interventional

This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.

NCT ID: NCT02956850 Completed - Clinical trials for Hepatitis B, Chronic

A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531

Start date: December 12, 2016
Phase: Phase 1
Study type: Interventional

This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic hepatitis B. Part I will be conducted in two portions: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) which will include only healthy volunteers. Part II will commence after completion of the MAD portion of Part I and will include only Chronic Hepatitis B (CHB) participants.

NCT ID: NCT02952924 Completed - Clinical trials for Hepatitis B, Chronic

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants

Start date: December 14, 2016
Phase: Phase 1
Study type: Interventional

This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7049389 following oral administration in healthy volunteers and chronic HBV infected participants. Part 3 is a non-randomized, non-controlled, open-label part to assess the efficacy and safety of RO7049389 when administered in combination with standard-of-care therapies for up to 48 weeks in nucleos(t)ide (NUC)-suppressed and treatment-naive chronic hepatitis B (CHB) participants.

NCT ID: NCT02908191 Completed - Chronic Hepatitis B Clinical Trials

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will be a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging assessment of ABI-H0731 in non-cirrhotic, CHB patients.

NCT ID: NCT02888106 Completed - Clinical trials for Chronic Viral Hepatitis B With Delta-agent

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Start date: April 2016
Phase: Phase 2
Study type: Interventional

Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent

NCT ID: NCT02881008 Completed - Chronic Hepatitis B Clinical Trials

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

Start date: November 14, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.

NCT ID: NCT02876419 Completed - Clinical trials for Hepatitis B, Chronic

A Long Term Follow-up Study of Patients From the REP 301 Protocol

Start date: August 2016
Phase:
Study type: Observational

The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN). In this protocol, similar reduction/clearance of serum HBsAg and improved response to immunotherapy were observed in addition to clearance of serum HDV RNA. The REP 301 protocol was designed to include a 24 week follow-up period after treatment, however given the strong antiviral response against HBV and HDV infection in these patients, it is now important to extend the follow-up period in these patients to monitor over a longer period after treatment the safety and efficacy combined REP 2139-Ca / peg-IFN treatment in patients in the REP 301 protocol.